

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**VOLUNTARY ANNOUNCEMENT
RESTRUCTURING OF THE WUXI VACCINES COMPANIES**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcements of the Company dated February 18, 2020, May 20, 2019 and July 18, 2018 (the “**Announcements**”) in relation to, among other things, the joint venture established by the Company and Shanghai Hile Bio-pharmaceutical Co., Ltd. (上海海利生物技術股份有限公司) (“**Hile**”, a company listed on the Shanghai Stock Exchange (stock code: 603718)). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

The Company is pleased to announce that the Company and Hile intend to implement a series of restructuring steps (the “**Restructuring**”) involving WuXi Vaccines (Hong Kong) Limited and WuXi Vaccines Co., Ltd. (上海藥明海德生物技術有限公司) (collectively, the “**WuXi Vaccines Companies**”). As of the date hereof, the Company and Hile hold, directly and indirectly, 70% and 30% shareholding interests in each of the WuXi Vaccines Companies. Upon completion of the Restructuring, the Company and Hile will hold 70% and 30% shareholding interests in a new investment holding company, namely, WuXi Vaccines (Cayman) Inc., which will hold the entire shareholding interest in each of the WuXi Vaccines Companies. As such, the Restructuring does not change the percentage of shareholding interests held by the Company and Hile in the WuXi Vaccines Companies. It is believed that the Restructuring will streamline the shareholding structure of the WuXi Vaccines Companies, and thereby enables more efficient management and minimizes the administrative costs and expenses of the joint venture.

Further announcement(s) will be made by the Company as and when required.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, April 1, 2021

As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*